|
|
|
| Expression levels and clinical significance of long non-coding RNA lung adenocarcinoma metastasis-associated transcript-1 and microRNA-141 in placenta and serum of pregnant women with preeclampsia |
| Hainan Provincial People's Hospital (Hainan Hospital Affiliated to Hainan Medical College), Haikou, Hainan Province, 570311 |
|
|
|
|
Abstract To explore the expression levels and clinical significance of long non-coding RNA (LncRNA) lung adenocarcinoma metastasis-associated transcript-1 (MALAT1) and microRNA-141 (miR 141) in placenta and serum of pregnant women with preeclampsia (PE). Methods: A total of 45 pregnant women with PE were enrolled in study group and were divided into group A (24 women with mild PE) and group B (21 women with severe PE) according to the severity of their PE between May 2019 and May 2020. Another 45 normal pregnant women undergoing physical examination were enrolled in control group during the same period. The expression levels of LncRNA MALAT1 and miR 141 in placenta and serum of these women were detected, and the correlation between the LncRNA MALAT1 level and the miR 141 level was statistically analyzed. The diagnostic value of the LncRNA MALAT1 level combined with the miR 141 level for adverse pregnancy outcomes of the women with PE was analyzed by receiver operator characteristic (ROC) curve. Results: The levels of LncRNA MALAT1 in placenta and serum (0.58±0.19, 0.37±0.16) of the women in group B were significantly lower than those (0.76±0.20, 0.52±0.17) of the women in group A and those (1.03±0.24, 0.94±0.23) of the women in the control group. The levels of miR 141 in placenta and serum (1.52±0.27, 1.40±0.28) of the women in group B were significantly higher than those (1.19±0.25, 1.26±0.24) of the women in group A， and those (0.73±0.18, 1.06±0.20) of the women in the control group. The expression levels of LncRNA MALAT1 in placenta and serum of the women in group A were negatively correlated with their miR 141 levels in placenta and serum. In group A, the levels of LncRNA MALAT1 in placenta and serum of the women with adverse pregnancy outcomes were significantly lower than those women with normal pregnancy outcomes, and the miR 141 levels in placenta and serum of the women with adverse pregnancy outcomes were significantly higher (all P＜0.05). ROC curve showed that the area under the curve (AUC) of the LncRNA MALAT1 level combined with the miR 141 level in placenta (0.913) of the women with PE for predicting their adverse pregnancy outcomes was significantly higher than that (0.804) of the LncRNA MALAT1 level in placenta or that (0.750) of the miR 141 level in placenta alone (P＜0.05). The AUC of the LncRNA MALAT1 level combined with the miR 141 level in serum (0.929) of the women with PE for predicting their adverse pregnancy outcomes was significantly higher than that (0.732) of the LncRNA MALAT1 level in serum or that (0.805) of the miR 141 level in serum alone (P＜0.05). Conclusion: The expression of LncRNA MALAT1 levels in placenta and serum of the pregnant women with PE decrease, while the expression levels of their miR 141 levels increase, and both of which are related to the severity of PE of the women. The levels of LncRNA MALAT1 combined with miR 141 in placenta and serum can be used to predicate the adverse pregnancy outcomes of these women.
|
|
|
|
|
|
|
|
|
